Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (131-140 of 285) with videos related to

Pageof 29
Sort By:
Breast Cancer Research and Treatment|June 15, 2017
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancerRodrigo Goncalves, Katherine DeSchryver, Cynthia Ma, et al.
Cancer Research Communications|August 17, 2023
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding ProteinsJunkai Wang, Alexander B Saltzman, Eric J Jaehnig, et al.
The Journal of Clinical Investigation|March 27, 2012
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsCynthia X Ma, Shirong Cai, Shunqiang Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozoleMatthew J Ellis, Yu Tao, Oliver Young, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 27, 2021
Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United StatesLaura J McPherson, Elizabeth R Walker, Yi-Ting Hana Lee, et al.
JAMA|August 20, 2009
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis, Feng Gao, Farrokh Dehdashti, et al.
Journal of the National Cancer Institute|May 14, 2009
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerMaggie C U Cheang, Stephen K Chia, David Voduc, et al.
Cancers|December 29, 2020
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft ModelsZhanfang Guo, Tina Primeau, Jingqin Luo, et al.
Cancer Research|June 23, 2022
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast CancerRashi Kalra, Ching Hui Chen, Junkai Wang, et al.
Clinical Pharmacology and Therapeutics|May 28, 2021
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast CancerJunmei Cairns, Krishna R Kalari, James N Ingle, et al.
Pageof 29

Showing results (131-140 of 285) with videos related to

Sort By:
Pageof 29
Breast Cancer Research and Treatment|June 15, 2017
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancerRodrigo Goncalves, Katherine DeSchryver, Cynthia Ma, et al.
Cancer Research Communications|August 17, 2023
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding ProteinsJunkai Wang, Alexander B Saltzman, Eric J Jaehnig, et al.
The Journal of Clinical Investigation|March 27, 2012
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor modelsCynthia X Ma, Shirong Cai, Shunqiang Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozoleMatthew J Ellis, Yu Tao, Oliver Young, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 27, 2021
Dialysis Facility Profit Status and Early Steps in Kidney Transplantation in the Southeastern United StatesLaura J McPherson, Elizabeth R Walker, Yi-Ting Hana Lee, et al.
JAMA|August 20, 2009
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis, Feng Gao, Farrokh Dehdashti, et al.
Journal of the National Cancer Institute|May 14, 2009
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerMaggie C U Cheang, Stephen K Chia, David Voduc, et al.
Cancers|December 29, 2020
Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft ModelsZhanfang Guo, Tina Primeau, Jingqin Luo, et al.
Cancer Research|June 23, 2022
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast CancerRashi Kalra, Ching Hui Chen, Junkai Wang, et al.
Clinical Pharmacology and Therapeutics|May 28, 2021
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast CancerJunmei Cairns, Krishna R Kalari, James N Ingle, et al.
Pageof 29